So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, Dendreon, Provenge, sipuleucel-T, surveillance, trial | 1 Comment »
At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.
Filed under: Uncategorized | Tagged: Dendreon, Provenge, sipuleucel-T, Valeant | Leave a comment »
According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.
Filed under: Uncategorized | Tagged: Dendreon, Provenge, sipuleucel-T | Leave a comment »
According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T | 3 Comments »
The signals from Dendreon in September last year were that it would take the company until at least the end of 2011 to be able to “ramp up” to full manufacturing capacity for its prostate cancer immunotherapeutic agent, sipuleucel-T (Provenge), even if the FDA does approve this product in May or June of 2010 — which is what most people are currently expecting. … READ MORE …
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | Leave a comment »
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: androgen-independent prostate cancer, Dendreon, Provenge, sipuleucel-T | 2 Comments »
